Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Extension of Lesinurad Monotherapy in Gout
2012-002956-18Phase 3Terminated
- Sponsor
- Ardea Biosciences, Inc.
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lesinurad in gout, sponsored by Ardea Biosciences, Inc. Primary endpoints: Long-term efficacy of lesinurad monotherapy and Long-term safety of lesinurad monotherapy. Started Aug 2012; status: terminated.
02
Drugs
lesinurad
03
Conditions
gout
Beyond the preview
Go deeper on 2012-002956-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002956-18.